Mereo BioPharma Details Anti-TIGIT Study And Attracts US Investors
Raises $70m In Private Placement
Mereo BioPharma’s completed private placement in the US will support clinical studies of its candidate immuno-oncology product etigilimab and a later-stage anti-sclerotin antibody product with potential in the treatment of brittle bone disease.
